Evidence map›Paper›PMID 40640335›Full record

ArticleOncogene2025

Salvage therapy with allogeneic invariant natural killer cells in a heavily pre-treated germ cell tumor.

Benjamin Garmezy, Joseph E Grossman, Jennifer Buell, Thiago Favano, Justin Stebbing, Steven O'Day, Marco A Purbhoo, Dhan Chand, F Anthony Greco

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Benjamin GarmezySarah Cannon Research Institute, Nashville, TN, USA. Ben.garmezy@scri.com.ORCID http://orcid.org/0000-0003-2790-6235
Joseph E GrossmanAgenus Inc, Lexington, MA, USA.
Jennifer BuellAgenus Inc, Lexington, MA, USA.ORCID http://orcid.org/0000-0001-7405-0076
Thiago FavanoAgenus Inc, Lexington, MA, USA.ORCID http://orcid.org/0000-0002-3927-2025
Justin StebbingSchool of Life Sciences, Anglia Ruskin University, Cambridge, UK.ORCID http://orcid.org/0000-0002-1117-6947
Steven O'DayAgenus Inc, Lexington, MA, USA.
Marco A PurbhooMiNK Therapeutics, Lexington, MA, USA.ORCID http://orcid.org/0009-0001-5541-5233
Dhan ChandAgenus Inc, Lexington, MA, USA.
F Anthony GrecoSarah Cannon Cancer Center, Tennessee Oncology, Nashville, TN, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Invariant natural killer T (iNKT) cells, previously considered to be tissue-resident, are an emerging and versatile allogeneic cell therapy with potent anti-tumor activity, acting at the interplay between innate and adaptive immune responses. We report an unprecedented complete remission in a heavily pre-treated metastatic germ cell neoplasm, using ex vivo expanded allogeneic iNKT cells, warranting further trials.

Indexed as

Immunotherapy, AdoptiveNatural Killer T-CellsNeoplasms, Germ Cell and EmbryonalSalvage TherapyTesticular NeoplasmsHumansMaleMiddle AgedTransplantation, Homologous

Identifiers

PMID40640335
PMCPMC12301233

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.